Diagnosis and management of multiple myeloma: a review
Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
Chromosome 1q21 abnormalities in multiple myeloma
Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the …
M D'agostino, DA Cairns, JJ Lahuerta… - Journal of clinical …, 2022 - ingentaconnect.com
PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a …
SZ Usmani, A Hoering, S Ailawadhi, R Sexton… - The Lancet …, 2021 - thelancet.com
Background The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t (11; 14) multiple myeloma
JL Kaufman, C Gasparetto… - American journal of …, 2021 - Wiley Online Library
Venetoclax (Ven) is a selective small‐molecule inhibitor of BCL‐2 that exhibits antitumoral
activity against MM cells with t (11; 14) translocation. We evaluated the safety and efficacy of …
activity against MM cells with t (11; 14) translocation. We evaluated the safety and efficacy of …
Multiple myeloma with high-risk cytogenetics and its treatment approach
I Hanamura - International Journal of Hematology, 2022 - Springer
Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …
Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications
IJ Cardona-Benavides, C de Ramón, NC Gutiérrez - Cells, 2021 - mdpi.com
Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …
Gain/amplification of chromosome arm 1q21 in multiple myeloma
I Hanamura - Cancers, 2021 - mdpi.com
Simple Summary Multiple myeloma (MM), a plasma cell neoplasm, is an incurable
hematological malignancy. Gain/amplification of chromosome arm 1q21 (1q21+) is the most …
hematological malignancy. Gain/amplification of chromosome arm 1q21 (1q21+) is the most …
High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma
L Bertamini, S Oliva, D Rota-Scalabrini… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE High levels of circulating tumor plasma cells (CTC-high) in patients with multiple
myeloma are a marker of aggressive disease. We aimed to confirm the prognostic impact …
myeloma are a marker of aggressive disease. We aimed to confirm the prognostic impact …
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
KH Maclachlan, EH Rustad, A Derkach… - Nature …, 2021 - nature.com
Abstract Chromothripsis is detectable in 20–30% of newly diagnosed multiple myeloma
(NDMM) patients and is emerging as a new independent adverse prognostic factor. In this …
(NDMM) patients and is emerging as a new independent adverse prognostic factor. In this …